278. Huge lymphatic malformation with cervicofacial lesion Clinical trials / Disease details


Clinical trials : 19 Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04861064
(ClinicalTrials.gov)
January 18, 202223/4/2021Weekly Sirolimus TherapyWeekly Sirolimus Therapy for the Treatment of Venous and Lymphatic MalformationsVenous Malformation;Lymphatic MalformationDrug: SirolimusMedical University of South CarolinaNULLRecruiting2 YearsN/AAll24Phase 2United States
2NCT04921722
(ClinicalTrials.gov)
October 22, 20216/6/2021Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular AnomaliesPercutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled TrialKaposiform Hemangioendothelioma;Tufted Angioma;Superficial Vascular Anomalies;Superficial Lymphatic MalformationsDrug: Percutaneous sirolimus;Drug: Oral sirolimusChildren's Hospital of Fudan UniversityNULLRecruiting0 Years18 YearsAll75Phase 4China
3NCT04994002
(ClinicalTrials.gov)
September 3, 202120/7/2021A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsA Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic MalformationsLymphatic MalformationDrug: CERC-006Cerecor IncNULLRecruiting18 Years31 YearsAll10Phase 1United States
4NCT04128722
(ClinicalTrials.gov)
February 14, 202024/9/2019TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUNTOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUNLingual Microcystic Lymphatic MalformationsDrug: Sirolimus Oral Liquid Product 1mg/mLUniversity Hospital, ToursNULLRecruiting5 YearsN/AAll12Phase 2France
5JPRN-UMIN000038973
2020/01/0625/12/2019A multicenter, phase 3 study assessing efficacy and safety of the Sirolimus (Granules and Tablets) in the Treatment of intractable vascular anomaliesA multicenter, phase 3 study assessing efficacy and safety of the Sirolimus (Granules and Tablets) in the Treatment of intractable vascular anomalies - Sirolimus for Intractable Vascular Anomalies(SIVA) Kaposiform hemangioendothelioma or Tufted angiomaLymphangioma (cystic lymphatic malformation), lymphangiomatosis (generalized lymphatic anomaly) or Gorham-Stout diseaseVenous malformation or blue rubber bleb nevus syndromeComplex-combined vascular malformations or Klippel-Trenanay-Weber syndromeAn initial dose of sirolimus is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL.Gifu University HospitalNULLComplete: follow-up continuing1months-oldNot applicableMale and Female10Phase 3Japan
6EUCTR2019-001530-33-FR
(EUCTR)
29/06/201901/04/2019TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUNTOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN - TOPGUN Lingual microcystic lymphatic malformations (LMLM) in children and adults
MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: RAPAMUNE
Product Name: Sirolimus 1mg/mL
Product Code: L04AA10
CHRU TOURSNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
12 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance
7NCT03972592
(ClinicalTrials.gov)
June 5, 201924/5/2019Topical Sirolimus in Cutaneous Lymphatic Malformations0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical TrialVascular Malformations;Lymphatic MalformationDrug: Topical 0.1% Sirolimus;Drug: Topical VehicleUniversity Hospital, ToursUniversity Hospital, AngersRecruiting6 YearsN/AAll55Phase 2France
8EUCTR2018-001359-11-FR
(EUCTR)
22/02/201923/07/20180.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICAL Cutaneous microcystic lymphatic malformations (CMLM) in children and adults
MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Sirolimus 0,1% crème
INN or Proposed INN: SIROLIMUS
CHRU TOURSNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
55 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance
9JPRN-UMIN000030522
2017/11/1422/12/2017A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesA multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomalies Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformationsBody surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Gifu UniversityNULLRecruitingNot applicableNot applicableMale and Female50Not selectedJapan
10JPRN-jRCTs041190036
03/08/201704/06/2019Visualization of lymphatic malformationThe efficacy of local injection of indocyanine green for visualizing lymphatic malformation lymphatic malformationLocal injection of indocyanine greenAitaro TakimotoNULLRecruitingNot applicableNot applicableBoth25Phase 2Japan
11JPRN-UMIN000025845
2017/03/0125/01/2017The efficacy of local injection of indocyanine green for visualizing lymphatic malformationThe efficacy of local injection of indocyanine green for visualizing lymphatic malformation - Visualization of lymphatic malformation lymphatic malformationLocal injection of indocyanine greenNagoya University Graduate School ofMedicineNULLRecruiting1years-old30years-oldMale and Female25Not selectedJapan
12JPRN-jRCTs031180265
10/08/201613/03/2019Study of bleomycin and OK-432 combined scletotherapy for LMsClinical study of bleomycin and OK-432 combined local injection sclerotherapy for intractable lymphatic malformations Lymphangioma (lymphatic malformation, common or cystic lymphatic malformation), and other lymphatic
lymphangioma, lymphatic malformation,;D18.1
OK-432 and bleomycin slolution (0.05 kE / mL and 0.5 mg / mL, respectively) will be injected into the lesion with water-soluble contrast agent Maximum dose of bleomycin is 10 mg /dose and 5 mg/kgBW.Cumulative maximum dose in repeated treatment is 10 mg/kgBWFujino AkihiroNULLNot RecruitingNot applicableNot applicableBoth21N/AJapan
13NCT02335242
(ClinicalTrials.gov)
May 23, 20157/1/2015Sildenafil for the Treatment of Lymphatic MalformationsPhase 2 Study of Sildenafil for the Treatment of Lymphatic MalformationsLymphatic Malformations;Lymphatic DiseasesDrug: Sildenafil 20 mg tablets;Other: Placebo tablets (resembling Revatio)Stanford UniversityAnn & Robert H Lurie Children's Hospital of ChicagoActive, not recruiting6 Months10 YearsAll18Phase 2United States
14ChiCTR-OPC-16008702
2014-05-012016-06-22Efficacy and safety of oral sildenafil in the treatment of pediatric lymphatic malformations in ChinaSildenafil in the treatment of pediatric lymphatic malformations pediatric lymphatic malformationsSildenafil-treated group:oral sildenafil;Beijing Children's HospitalNULLRecruitingBothSildenafil-treated group:40;China
15JPRN-UMIN000008498
2012/07/2524/07/2012Propranolol for a treatment of lymphatic malformationPropranolol for a treatment of lymphatic malformation - Propranolol study for lymphatic malformation lymphatic malformationpropranolol therapyUniversity of TokyoNULLComplete: follow-up completeNot applicable65years-oldMale and Female20Phase 2Japan
16NCT01212965
(ClinicalTrials.gov)
September 201024/9/2010Selenium in the Treatment of Complicated Lymphatic MalformationsPilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young AdultsLymphatic MalformationsDrug: SeleniumMedical College of WisconsinNULLTerminated14 Years30 YearsBoth5Phase 1United States
17NCT00975819
(ClinicalTrials.gov)
October 200910/9/2009Safety and Efficacy Study of Sirolimus in Complicated Vascular AnomaliesA Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular AnomaliesKaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia SyndromesDrug: sirolimusChildren's Hospital Medical Center, CincinnatiNULLActive, not recruitingN/A31 YearsBoth60Phase 2United States
18NCT00010452
(ClinicalTrials.gov)
April 20002/2/2001Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic MalformationsTreatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter TrialLymphatic MalformationsDrug: picibanilUniversity of IowaNULLCompleted6 Months18 YearsBoth150Phase 2/Phase 3United States
19NCT03427619
(ClinicalTrials.gov)
January 1, 199810/1/2018OK432 (Picibanil) in the Treatment of Lymphatic MalformationsOK432 (Picibanil) in the Treatment of Lymphatic MalformationsLymphatic MalformationsDrug: OK432Richard JH SmithNULLCompleted6 Months17 YearsAll701Phase 4United States